Contraception for young people - 27 July 2012
A contraception request is the second most common general practice presentation for females aged 14–17 years.
Contraceptive choices for younger women are in general no different to other age groups. The clinical issues are usually focused on establishing rapport, assessing maturity in decision making, capacity to consent to clinical management and child protection considerations.
Confidentiality is highly valued by young people and it is important to be explicit about rights. Other relevant issues include ability to pay for ongoing supplies, privacy of method, increased risk of sexually transmissible infections (STIs) and high fertility.
From a medical perspective there is no lower age limit for prescribing hormonal contraception if the young woman has started menstruating. The age of consent to medical treatment is 18.
However, the common law position in most states and territories is that a younger person can consent to their own treatment if they are judged as a mature minor.
A discussion about parental involvement should occur for those aged 16 or younger. Parental involvement removes the burden of keeping contraception secret, the surreptitious borrowing of Health Care or Medicare cards and it may assist with costs. In general, there are proven benefits of good parental communication.
While effective as STI prevention, condoms are not a good choice as a sole method of contraception with a typical use efficacy rate of 82% per year. Dual protection with the addition of a long acting reversible method of contraception (LARC) or the combined oral contraceptive pill (COCP) can be encouraged.
There is no legal lower age limit for dispensing of levonorgestrel emergency contraception (LNGEC) for young women assessed as mature minors. Advance provision may be appropriate in some circumstances as young women may experience barriers to over the counter supply.
Long-acting reversible contraceptives (larcs)
LARCs include contraceptive implants, injections and intrauterine methods and are highly effective, cost effective and underutilised in the Australian setting. Recently pregnant adolescents who chose a LARC substantially lower their risk of a rapid repeat pregnancy compared with those choosing the pill or condoms.
The etonogestrel implant (Implanon NXT) is highly recommended as a first line choice for young women. It is more than 99.9% effective, cheap and lasts up to three years. Negative attitudes around bleeding patterns, weight gain and long term effects exist. The implant is rapidly reversible and has no effect on future fertility. 25% of women will experience frequent and/or prolonged bleeding, 60% will have minimal or no bleeding. There is no proven effect on increase in weight gain,1 and acne and dysmenorrhoea often improve.
Depot medroxyprogesterone acetate injections (DMPA)
DMPA injections can be a good choice, although generally not first-line in women under 18 because of bone density concerns. Bone density decreases during use but is likely to recover after cessation. It is very effective, has a 50% chance of amenorrhoea, and is unaffected by liver-enzyme inducing medications including anti-epileptics. Its use can easily be concealed from other people.
Early weight gain is predictive of ongoing gain but only occurs in around 20% of users.
Intrauterine devices (IUDs)
IUDs are increasingly used worldwide in nulliparous as well as parous young women. The advantages outweigh the disadvantages in most circumstances. Nulliparity can be associated with an increased risk of expulsion as well as removal for bleeding and pain.
Young women are also at higher risk of chlamydia infection, so it is important to encourage the use of condoms, thus giving dual protection against unintended pregnancy and STIs.
Combined hormonal methods (cocp and vaginal ring)
The COCP or vaginal ring can be a good choice for young women. While young women rarely have serious medical conditions that might contraindicate use, consideration needs to be given to issues such a BMI.>.35kg/m2 or migraine with aura or thrombophilia.
Benefits include improvement in dysmenorrhoea, heavy menstrual bleeding and acne as well as the ability to manipulate bleeding cycles. Disadvantages include a typical use failure rate of 9% per year.
Progestogen only pill (pop)
The POP is generally not recommended for young women, due to its strict timing regime and higher failure rates in this age group.
There are a number of important requirements for contraception in younger women including:
1. Guazzelli CA, de Queiroz FT, Barbieri M, Torloni MR, de Araujo FF. Etonogestrel implant in adolescents: evaluation of clinical aspects. Contraception. 2011;83(4):336-9.
2. Harrison C, Charles J, Britt H. Contraception. Australian family physician. 2011;40(3):93.
3. Baxter S, Blank L, Guillaume L, Squires H, Payne N. Views of contraceptive service delivery to young people in the UK: a systematic review and thematic synthesis. The journal of family planning and reproductive health care / Faculty of Family Planning & Reproductive Health Care, Royal College of Obstetricians & Gynaecologists. 2011;37(2):71-84.
4. Reddy DM, Fleming R, Swain C. Effect of mandatory parental notification on adolescent girls' use of sexual health care services. Jama. 2002;288(6):710-4.
5. Jones RK, Purcell A, Singh S, Finer LB. Adolescents' reports of parental knowledge of adolescents' use of sexual health services and their reactions to mandated parental notification for prescription contraception. Jama. 2005;293(3):340-8.
6. Faculty of Sexual & Reproductive Healthcare Clinical Guidance. Clinical Effectiveness Unti. Contraceptive Choices for Young People. 2010. [Accessed 09/12/2011]. Available from: http://www.fsrh.org/pdfs/ceuGuidanceYoungPeople2010.pdf.
7. Bird S. Consent to medical treatment: the mature minor. Australian family physician. 2011;40(3):159-60.
8. DiClemente RJ, Wingood GM, Crosby R, Cobb BK, Harrington K, Davies SL. Parent-adolescent communication and sexual risk behaviors among African American adolescent females. The Journal of pediatrics. 2001;139(3):407-12.
9. Karofsky PS, Zeng L, Kosorok MR. Relationship between adolescent-parental communication and initiation of first intercourse by adolescents. J Adolesc Health. 2001;28(1):41-5.
10. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404.
11. Hussainy SY, Stewart K, Chapman CB, Taft AJ, Amir LH, Hobbs MK, et al. Provision of the emergency contraceptive pill without prescription: attitudes and practices of pharmacists in Australia. Contraception. 2011;83(2):159-66.
12. Lewis LN, Doherty DA, Hickey M, Skinner SR. Predictors of sexual intercourse and rapid-repeat pregnancy among teenage mothers: an Australian prospective longitudinal study. Med J Aust. 2010;193(6):338-42.
13. Templeman CL, Cook V, Goldsmith LJ, Powell J, Hertweck SP. Postpartum contraceptive use among adolescent mothers. Obstet Gynecol. 2000;95(5):770-6.
14. Roberts H, Silva M, Xu S. Post abortion contraception and its effect on repeat abortions in Auckland, New Zealand. Contraception. 2010;82(3):260-5.
15. Lewis LN, Doherty DA, Hickey M, Skinner SR. Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy. Contraception. 2010;81(5):421-6.
16. Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception. 2009;80(6):527-32.
17. Spies EL, Askelson NM, Gelman E, Losch M. Young women's knowledge, attitudes, and behaviors related to long-acting reversible contraceptives. Women's health issues : official publication of the Jacobs Institute of Women's Health. 2010;20(6):394-9.
18. Glasier A, Scorer J, Bigrigg A. Attitudes of women in Scotland to contraception: a qualitative study to explore the acceptability of long-acting methods. J Fam Plann Reprod Health Care. 2008;34(4):213-7.
19. Huber J, Wenzl R. Pharmacokinetics of Implanon. An integrated analysis. Contraception. 1998;58(6 Suppl):85S-90S.
20. Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception. 1998;58(6 Suppl):91S-7S.
Content updated 27 July 2012